The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of ...
BioArctic’s partner Eisai announces update on regulatory review of lecanemab to treat early Alzheimer’s disease in EU: Stockholm Monday, February 3, 2025, 13:00 Hrs [IST] BioA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback